Uncategorized
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, and manicuring the Pharmalot campus. We also hope to hold still another listening party, where the rotation will likely feature this, this, this, this and this. And what about you? If the weather cooperates, the possibilities are endless — hiking, surfing, sunbathing, strolling, gazing at the stars in the sky. Maybe you want to try a new restaurant. You could also do something meaningful and reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
A U.S. Food and Drug Administration advisory panel voted 10-to-3 to recommend use of an experimental Replimune treatment for advanced melanoma, STAT writes. The panel determined the company collected sufficient data to allow the FDA to review RP1, an engineered viral immunotherapy. What comes next could be seen by some as a signal of how the FDA, which is under new leadership, weighs potential benefits and risks for investigational drugs. RP1 was initially rejected last year and again this past April. Investors have interpreted the decision to hold an advisory committee meeting as a sign of new lenience.
The weight loss drug boom is beginning to show signs of a slowdown as employers and insurers pull back on coverage, signaling the market could be entering a more restrained phase after years of breakneck expansion, Bloomberg News says. In the past few months, growth in prescriptions for GLP-1 drugs for weight loss have moderated, according to Cigna chief executive officer Brian Evanko. The insurer’s pharmacy benefits manager has seen coverage declines and slower utilization growth compared to prior periods. About 6% of big employers dropped coverage for the drugs in 2026, according to a recent survey from consulting firm Mercer.
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, and manicuring the Pharmalot campus. We also hope to hold still another listening party, where the rotation will likely feature this, this, this, this and this. And what about you? If the weather cooperates, the possibilities are endless — hiking, surfing, sunbathing, strolling, gazing at the stars in the sky. Maybe you want to try a new restaurant. You could also do something meaningful and reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
A U.S. Food and Drug Administration advisory panel voted 10-to-3 to recommend use of an experimental Replimune treatment for advanced melanoma, STAT writes. The panel determined the company collected sufficient data to allow the FDA to review RP1, an engineered viral immunotherapy. What comes next could be seen by some as a signal of how the FDA, which is under new leadership, weighs potential benefits and risks for investigational drugs. RP1 was initially rejected last year and again this past April. Investors have interpreted the decision to hold an advisory committee meeting as a sign of new lenience.
The weight loss drug boom is beginning to show signs of a slowdown as employers and insurers pull back on coverage, signaling the market could be entering a more restrained phase after years of breakneck expansion, Bloomberg News says. In the past few months, growth in prescriptions for GLP-1 drugs for weight loss have moderated, according to Cigna chief executive officer Brian Evanko. The insurer’s pharmacy benefits manager has seen coverage declines and slower utilization growth compared to prior periods. About 6% of big employers dropped coverage for the drugs in 2026, according to a recent survey from consulting firm Mercer.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read